Executive interview: Volition FY22 earnings

Volition is a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis (NETs), such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to prolong the life of patients and improve their quality of life. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

In this video, Cameron Reynolds, Volition’s chief executive officer, discusses the company’s FY22 results. During the year, the team executed a global licensing and supply agreement with Heska Corporation to distribute the Nu.Q Vet Cancer test at the point of care. Volition also executed a global supply agreement with IDEXX Laboratories, as a provider of the Nu.Q Vet Cancer test through its reference laboratory network for cancer indications in animal health. Significant progress was made with the development of the Nu.Q NETs product pillar, including the receipt of a CE Mark for the test and engaging Diagnostic Oncology CRO to spearhead the clinical product development and FDA regulatory programs.